TELA Bio, Inc. (TELA) Stock Profile — Insider Trades & Financials

Revenue$20.9M

Net Income-$9.0M

EPS$-0.66

Gross Margin65.9%

Market Cap$28.5M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Antony Koblish

CEO & Executive Director

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Founded: 2012
Employees: 209

⚡

Core Efficiency

ROE?

-143.21%

ROA?

-11.10%

D/E Ratio?

11.90

Op. Margin?

-31.86%

📊

Profitability Ratios

Net Margin?

-43.32%

Loading company sections...

TELA Bio, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness